STOCK TITAN

WINDWARD BIO GROUP (WWB) SEC Filings

WWB NASDAQ
Rhea-AI Summary

Windward Bio Group AG (WWB) is offering 10,294,117 common shares in its IPO at $17.00 per share, for an aggregate offering price of $174,999,989.00 and proceeds to the company of $162,749,989.77 before expenses. Sanofi has agreed to buy 1,532,691 shares and pre-funded warrants for 1,408,485 shares for $50.0 million in a private placement, conditioned on and expected to close concurrently with the IPO; the IPO is not contingent on that placement.

Based on its current operating plan, Windward Bio expects existing resources and net proceeds from the IPO and concurrent private placement to fund specified trials and operations into the first half of 2029. WIN378 is in Phase 2/3 asthma and Phase 2 COPD studies; WIN027 is in Phase 1. The Phase 2 portion of POLARIS-1 enrolled 147 patients; no treatment-related serious adverse events, withdrawals or discontinuations had been observed to date, though the company cautions early results may not predict later trials.

Windward Bio reported a net loss of $42.6 million for the six months ended June 30, 2026, versus $22.75 million in the same 2025 period. It had $207.3 million in cash, cash equivalents and marketable securities at June 30, 2026, and a preliminary, unaudited estimate of $181.8 million at September 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Windward Bio Group AG (WWB) Form 3 lists OrbiMed Private Investments IX, LP as record holder of 3,561,936 Series A preferred shares, 1,611,008 Series B preferred shares, 216,668 warrants and 531,632 common shares as of November 12, 2026. The preferred shares convert on a 1-to-1 basis into common shares immediately before the initial public offering closes; the warrants are exercisable at $0.02 and expire May 12, 2036. OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC may be deemed to have voting and investment power, but disclaim beneficial ownership except to the extent of any pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

WINDWARD BIO GROUP AG director Iqbal Rasool Mufti is identified as a reporting person in a Form 3 ownership filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Windward Bio Group AG (WWB) director David P. Bonita disclosed positions held of record by OrbiMed Private Investments IX, LP: 3,561,936 and 1,611,008 Common Shares underlying Series A and Series B Preferred Shares, respectively; 216,668 underlying warrants; and 531,632 Common Shares. The preferred shares convert one-for-one immediately before the issuer’s IPO. Warrants are exercisable at $0.02 and expire May 12, 2036. Bonita, an OrbiMed Advisors member, disclaims beneficial ownership except to the extent of any pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Windward Bio Group AG (WWB) Chief Executive Officer Luca Santarelli reported direct holdings of 4,578,110 common shares and an employee share option covering 163,854 common shares as of November 12, 2026. The option has a $0.0200 exercise price and expires April 30, 2036. It vested or will vest in 36 equal monthly installments on the last day of each relevant month beginning April 30, 2026, subject to continuous service on each vesting date. The exercise price reflects conversion from CHF at an exchange rate of $1.122 to CHF 1.00 as of November 6, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

As of November 12, 2026, Windward Bio Group AG (WWB) Chief Medical Officer Omar Khwaja reported direct ownership of 642,136 common shares and an option covering 318,830 common shares.

The option has a $0.02 exercise price and expires April 30, 2036. It vested or will vest in 36 equal monthly installments on the last day of each relevant month, beginning April 30, 2026, subject to Khwaja’s continuous service on each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

WINDWARD BIO GROUP AG (WWB) lists preferred-share holdings held by Omega Fund VII, L.P. and Omega Fund VIII, L.P., in connection with director Otello Stampacchia. As of November 12, 2026, Omega VII held 1,262,628 Series A and 531,632 Series B Preferred Shares; Omega VIII held 1,262,626 Series A and 531,634 Series B Preferred Shares. Stampacchia disclaims beneficial ownership except to the extent of any pecuniary interest.

Each Series A and Series B Preferred Share automatically converts into Common Shares on a 1 to 1 basis immediately prior to the closing of the issuer’s initial public offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

WINDWARD BIO GROUP AG (WWB) Chief Financial Officer Claudia D'Augusta reported direct ownership of 927,760 common shares and an employee share option covering 33,206 underlying common shares on November 12, 2026. The option has an exercise price of $0.02 per share and expires April 30, 2036. It vested or will vest in 36 equal monthly installments beginning April 30, 2026, subject to continuous service on each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

WINDWARD BIO GROUP AG Chief Operating Officer Kevin Andrew Harris reported direct ownership of 927,760 common shares as of November 12, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many WINDWARD BIO GROUP (WWB) SEC filings are available on StockTitan?

StockTitan tracks 12 SEC filings for WINDWARD BIO GROUP (WWB). Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for WINDWARD BIO GROUP (WWB)?

The most recent SEC filing for WINDWARD BIO GROUP (WWB) was filed on November 13, 2026.